Immunovant, Inc. (IMVT)
26.01
-0.17
(-0.65%)
USD |
NASDAQ |
Jan 23, 16:00
26.19
+0.18
(+0.69%)
After-Hours: 20:00
Immunovant Research and Development Expense (TTM): 403.62M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Revvity, Inc. | 206.87M |
| Viridian Therapeutics, Inc. | 321.22M |
| Perspective Therapeutics, Inc. | 61.22M |
| Electromed, Inc. | 1.071M |
| InfuSystem Holdings, Inc. | -- |